Delivered
Michigan
Destination state
Carrier-confirmed deliveryThe supplied tracking record shows this shipment as delivered.
Recipient details withheld
Medical Review Statement
Educational content updated October 1, 2026 using the sources listed below. Medically reviewed by Dr. Fremlin Dekyi, MD. Reviewed: October 1, 2026. This content does not replace individualized medical advice.
Quick Answer
Who qualifies? The immediate answer
For adult weight-management treatment with Wegovy, usual eligibility is BMI at least 30, or BMI at least 27 with one or more weight-related conditions. Examples include high blood pressure, abnormal cholesterol, type 2 diabetes or obstructive sleep apnea. Eligibility still requires an individualized safety assessment.
BMI and weight-management eligibility
| Adult BMI | Typical weight-management consideration |
|---|---|
| Below 27 | Generally does not meet usual weight-management criteria; other product-specific indications may differ |
| 27 to below 30 | At least one weight-related condition is usually required |
| 30 or higher | Obesity criterion is generally met; clinician safety assessment is still required |
What BMI cannot tell your clinician
BMI is a screening tool, not a full measure of health, body composition or treatment need. The clinician also reviews your health history, previous treatment, medicines, goals and the ability to maintain adequate nutrition. Insurance authorization has separate requirements.
Who should not use it, and who needs extra evaluation
Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma, MEN 2 or prior serious hypersensitivity to semaglutide. Weight-management treatment is not appropriate during pregnancy; discuss stopping at least 2 months before planned pregnancy.
A history of pancreatitis, gallbladder disease, diabetic retinopathy, severe gastroparesis, dehydration or medicines that cause hypoglycemia requires specific review. These are not all identical to absolute contraindications.
Wegovy eligibility is different from Ozempic eligibility
Ozempic is intended for adults with type 2 diabetes and has additional diabetes-related cardiovascular and kidney indications. It is not approved for chronic weight management. Wegovy injection also has adolescent and additional adult indications; this page's BMI summary concerns adult weight-management use.
What to expect from clinician evaluation
Provide height, weight, medication list, allergies, weight-related diagnoses and pregnancy plans. Your clinician may request glucose or A1c results, kidney function or other tests based on your history. Online assessment may need an in-person examination. A BMI result alone cannot establish approval.
What to discuss with your clinician
- Your diagnosis, treatment goals and medical history.
- The exact product, dose, safety precautions and ongoing cost.
- Your follow-up plan and symptoms that need prompt assessment.
Best next step
Use consultation to turn search intent into a real treatment decision
Patients usually get more value from medical review, fit assessment, and follow-up planning than from choosing a medication based only on headlines or social posts.
Frequently asked questions
You may meet usual adult weight-management criteria if you also have a qualifying weight-related condition. Your clinician and insurer assess their own requirements.
No. Wegovy weight-management eligibility does not require diabetes. Ozempic has a different approved purpose.
No. Insurers may require prior authorization, documentation, step therapy or other criteria; some plans exclude obesity medicines.
